CY1121038T1 - Θεραπεια καρκινου μαστου - Google Patents

Θεραπεια καρκινου μαστου

Info

Publication number
CY1121038T1
CY1121038T1 CY181101174T CY181101174T CY1121038T1 CY 1121038 T1 CY1121038 T1 CY 1121038T1 CY 181101174 T CY181101174 T CY 181101174T CY 181101174 T CY181101174 T CY 181101174T CY 1121038 T1 CY1121038 T1 CY 1121038T1
Authority
CY
Cyprus
Prior art keywords
breast cancer
cancer treatment
compounds
iii
triple
Prior art date
Application number
CY181101174T
Other languages
Greek (el)
English (en)
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Original Assignee
Medivation Prostate Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121038(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc filed Critical Medivation Prostate Therapeutics Llc
Publication of CY1121038T1 publication Critical patent/CY1121038T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY181101174T 2011-07-29 2018-11-08 Θεραπεια καρκινου μαστου CY1121038T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
CY1121038T1 true CY1121038T1 (el) 2019-12-11

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101174T CY1121038T1 (el) 2011-07-29 2018-11-08 Θεραπεια καρκινου μαστου

Country Status (18)

Country Link
US (4) US9517229B2 (enExample)
EP (4) EP3610731A1 (enExample)
JP (2) JP6158180B2 (enExample)
KR (1) KR101923250B1 (enExample)
CN (1) CN103997894B (enExample)
BR (1) BR112014002200A2 (enExample)
CA (1) CA2843417C (enExample)
CY (1) CY1121038T1 (enExample)
DK (1) DK2739153T3 (enExample)
EA (1) EA028452B1 (enExample)
ES (1) ES2696074T3 (enExample)
HU (1) HUE040524T2 (enExample)
MX (1) MX359664B (enExample)
PH (1) PH12014500248B1 (enExample)
PL (1) PL2739153T3 (enExample)
PT (1) PT2739153T (enExample)
SI (1) SI2739153T1 (enExample)
WO (1) WO2013066440A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103997894B (zh) * 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
PT3305285T (pt) 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
BR112015026257B1 (pt) * 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
JP6568093B2 (ja) * 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
CA2970469A1 (en) 2014-12-12 2016-06-16 Amy Christian Peterson Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
WO2016141161A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ，エルエルシー 肥満細胞症の治療のための併用療法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ，エルエルシー 消化管間質腫瘍の治療のための併用療法
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
JP2023536636A (ja) * 2020-08-03 2023-08-28 オンコサイト・コーポレイション 腫瘍の分類及び応答性の予測
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
PL3412290T3 (pl) * 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US8680291B2 (en) * 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
SG10201402628VA (en) * 2009-02-24 2014-10-30 Medivation Prostate Therapeutics Inc Specific Diarylhydantoin And Diarylthiohydantoin Compounds
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) * 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
CN103997894B (zh) * 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
EP2888594B1 (en) 2012-08-23 2018-08-15 The Regents of the University of Colorado, a body corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
CA2970469A1 (en) 2014-12-12 2016-06-16 Amy Christian Peterson Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
SI2739153T1 (sl) 2018-12-31
MX2014001218A (es) 2014-08-22
PH12014500248B1 (en) 2018-08-31
BR112014002200A2 (pt) 2017-03-07
JP2017141269A (ja) 2017-08-17
WO2013066440A9 (en) 2013-07-18
EP2739153B1 (en) 2018-08-22
US20210069154A1 (en) 2021-03-11
EP2739153A4 (en) 2015-03-11
EP2739153A1 (en) 2014-06-11
EA201400178A1 (ru) 2014-11-28
JP2014524934A (ja) 2014-09-25
PH12014500248A1 (en) 2014-03-17
HK1201413A1 (en) 2015-09-04
EA028452B1 (ru) 2017-11-30
HUE040524T2 (hu) 2019-03-28
ES2696074T3 (es) 2019-01-14
EP3430907A1 (en) 2019-01-23
US20190262315A1 (en) 2019-08-29
MX359664B (es) 2018-10-05
CN103997894B (zh) 2016-08-24
EP3791724A1 (en) 2021-03-17
CA2843417C (en) 2018-08-21
US10111861B2 (en) 2018-10-30
US9517229B2 (en) 2016-12-13
EP3610731A1 (en) 2020-02-19
CA2843417A1 (en) 2013-05-10
KR20140107174A (ko) 2014-09-04
CN103997894A (zh) 2014-08-20
KR101923250B1 (ko) 2018-11-28
PT2739153T (pt) 2018-11-28
US20170087132A1 (en) 2017-03-30
WO2013066440A1 (en) 2013-05-10
PL2739153T3 (pl) 2019-04-30
DK2739153T3 (en) 2018-12-03
US20140296312A1 (en) 2014-10-02
JP6158180B2 (ja) 2017-07-05
HK1198867A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
CY1121038T1 (el) Θεραπεια καρκινου μαστου
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
MX383590B (es) Inhibidores de kdm1a para el tratamiento de enfermedades.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
SMT201600132B (it) Derivati fosforammidati di 5-fluoro-2'-desossiuridina per uso nel trattamento del cancro
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
ECSP15026557A (es) Compuestos y sus métodos de empleo
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX380943B (es) Compuestos terapeuticamente activos y sus metodos de uso.
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
CL2016000150A1 (es) Compuestos y composiciones como inhibidores de la mek
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
MA40076A (fr) Inhibiteurs de syk
NI201300112A (es) Composición que comprende aflibercept, ácido folínico, 5 - fluorouracilo (5 - fu) e irinotecano ( folfiri).
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
PH12015501088A1 (en) Dimeric compounds
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.